BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. (Q47920784)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 January 2017

Language	Label	Description	Also known as
English	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.	scientific article published on 24 January 2017

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

phase III clinical trial

0 references

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Christiane Copie Bergman

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Philippe Gaulard

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Thierry J Molina

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

T Petrella

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

J Brière

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

R Delarue

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

F Jardin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

P Ruminy

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

C Thieblemont

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

D Canioni

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

P Feugier

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

B Fabiani

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

M Parrens

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

M André

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

G A Salles

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

H Tilly

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

J P Jais

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

1 May 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1042-1049

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX022

21 January 2018

Identifiers

10.1093/ANNONC/MDX022

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28327893%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47920784&oldid=1527277238"